Arzeda

London-based vaccine company Vicebio Ltd. has become the 17th company this year to raise a nine-figure series B round, according to Evaluate data. TCGX led its $100m series B venture capital round,

Biopharmaceutical venture capital fundraising has not slowed its record-breaking pace during the holiday season and the VC boom has extended to life science tools and services, including two recent me